Literature DB >> 31730857

B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.

Daniel P Hollern1, Nuo Xu2, Aatish Thennavan3, Cherise Glodowski4, Susana Garcia-Recio1, Kevin R Mott1, Xiaping He1, Joseph P Garay1, Kelly Carey-Ewend1, David Marron1, John Ford1, Siyao Liu1, Sarah C Vick2, Miguel Martin5, Joel S Parker1, Benjamin G Vincent6, Jonathan S Serody7, Charles M Perou8.   

Abstract

This study identifies mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer. By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response. Further, we developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, we uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. We also show that B cell activation of T cells and the generation of antibody are key to immunotherapy response and propose a new biomarker for immune checkpoint therapy. In total, this work presents resources of new preclinical models of breast cancer with large mRNA-seq and single-cell RNA-seq datasets annotated for sensitivity to therapy and uncovers new components of response to immune checkpoint inhibitors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cells; CTLA4; PD1; T cells; TMB; breast cancer; genomics; immune checkpoints; immunotherapy; mouse models; tumor mutation burden

Mesh:

Substances:

Year:  2019        PMID: 31730857      PMCID: PMC6911685          DOI: 10.1016/j.cell.2019.10.028

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  70 in total

1.  B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen.

Authors:  Sheng Hong; Zhimin Zhang; Hongtao Liu; Meijie Tian; Xiping Zhu; Zhuqiang Zhang; Weihong Wang; Xuyu Zhou; Fuping Zhang; Qing Ge; Bing Zhu; Hong Tang; Zhaolin Hua; Baidong Hou
Journal:  Immunity       Date:  2018-10-02       Impact factor: 31.745

2.  Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.

Authors:  Nicholas A Taylor; Sarah C Vick; Michael D Iglesia; W June Brickey; Bentley R Midkiff; Karen P McKinnon; Shannon Reisdorf; Carey K Anders; Lisa A Carey; Joel S Parker; Charles M Perou; Benjamin G Vincent; Jonathan S Serody
Journal:  J Clin Invest       Date:  2017-08-21       Impact factor: 14.808

3.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Authors:  Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway
Journal:  Science       Date:  2015-09-10       Impact factor: 47.728

4.  Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Authors:  Jan Budczies; Anja Seidel; Petros Christopoulos; Volker Endris; Matthias Kloor; Balázs Győrffy; Barbara Seliger; Peter Schirmacher; Albrecht Stenzinger; Carsten Denkert
Journal:  Oncoimmunology       Date:  2018-10-19       Impact factor: 8.110

5.  Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Authors:  Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Authors:  Lance D Miller; Jeff A Chou; Michael A Black; Cristin Print; Julia Chifman; Angela Alistar; Thomas Putti; Xiaobo Zhou; Davide Bedognetti; Wouter Hendrickx; Ashok Pullikuth; Jonathan Rennhack; Eran R Andrechek; Sandra Demaria; Ena Wang; Francesco M Marincola
Journal:  Cancer Immunol Res       Date:  2016-04-28       Impact factor: 11.151

8.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

Review 9.  New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms.

Authors:  Meng Shen; Jian Wang; Xiubao Ren
Journal:  Front Immunol       Date:  2018-03-08       Impact factor: 7.561

10.  Prognostic value of B cells in cutaneous melanoma.

Authors:  Sara R Selitsky; Lisle E Mose; Christof C Smith; Shengjie Chai; Katherine A Hoadley; Dirk P Dittmer; Stergios J Moschos; Joel S Parker; Benjamin G Vincent
Journal:  Genome Med       Date:  2019-05-28       Impact factor: 11.117

View more
  118 in total

1.  Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.

Authors:  Di-Guang Wen; Xiao-Ping Zhao; Yu You; Zuo-Jin Liu
Journal:  Cancer Immunol Immunother       Date:  2020-09-28       Impact factor: 6.968

2.  Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

Authors:  Aranzazu Fernandez-Martinez; Ian E Krop; David W Hillman; Mei-Yin Polley; Joel S Parker; Lucas Huebner; Katherine A Hoadley; Jonathan Shepherd; Sara Tolaney; N Lynn Henry; Chau Dang; Lyndsay Harris; Donald Berry; Olwen Hahn; Clifford Hudis; Eric Winer; Ann Partridge; Charles M Perou; Lisa A Carey
Journal:  J Clin Oncol       Date:  2020-10-23       Impact factor: 44.544

3.  Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

Authors:  Li Zhang; Harini Kandadi; Hai Yang; Jason Cham; Tao He; David Y Oh; Nadeem A Sheikh; Lawrence Fong
Journal:  Cancer Immunol Res       Date:  2020-09-23       Impact factor: 11.151

Review 4.  Cancer systems immunology.

Authors:  Nathan E Reticker-Flynn; Edgar G Engleman
Journal:  Elife       Date:  2020-07-13       Impact factor: 8.140

Review 5.  Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.

Authors:  Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-14       Impact factor: 7.038

Review 6.  Breast cancer resistance mechanisms: challenges to immunotherapy.

Authors:  Ann Hanna; Justin M Balko
Journal:  Breast Cancer Res Treat       Date:  2021-07-28       Impact factor: 4.872

7.  Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.

Authors:  David A Wheeler; Naoko Takebe; Toshinori Hinoue; Katherine A Hoadley; Maria F Cardenas; Alina M Hamilton; Peter W Laird; Linghua Wang; Adrienne Johnson; Ninad Dewal; Vincent Miller; David Piñeyro; Manuel Castro de Moura; Manel Esteller; Hui Shen; Jean Claude Zenklusen; Roy Tarnuzzer; Lisa M McShane; James V Tricoli; Paul M Williams; Irina Lubensky; Geraldine O'Sullivan-Coyne; Elise C Kohn; Richard F Little; Jeffrey White; Shakun Malik; Lyndsay Harris; Carol Weil; Alice P Chen; Chris Karlovich; Brian Rodgers; Lalitha Shankar; Paula Jacobs; Tracy Nolan; Jianhong Hu; Donna M Muzny; Harshavardhan Doddapaneni; Viktoriya Korchina; Julie Gastier-Foster; Jay Bowen; Kristen Leraas; Elijah F Edmondson; James H Doroshow; Barbara A Conley; S Percy Ivy; Louis M Staudt
Journal:  Cancer Cell       Date:  2020-11-19       Impact factor: 31.743

Review 8.  B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments.

Authors:  Yuan Wei; Chun-Xiang Huang; Xiao Xiao; Dong-Ping Chen; Hong Shan; Huanhuan He; Dong-Ming Kuang
Journal:  Oncogene       Date:  2021-06-29       Impact factor: 9.867

9.  Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.

Authors:  Simon Eschweiler; James Clarke; Ciro Ramírez-Suástegui; Bharat Panwar; Ariel Madrigal; Serena J Chee; Ioannis Karydis; Edwin Woo; Aiman Alzetani; Somaia Elsheikh; C J Hanley; G J Thomas; Peter S Friedmann; Tilman Sanchez-Elsner; Ferhat Ay; Christian H Ottensmeier; Pandurangan Vijayanand
Journal:  Nat Immunol       Date:  2021-06-24       Impact factor: 25.606

Review 10.  Immunity beyond cancer cells: perspective from tumor tissue.

Authors:  Shengyu Gao; Ting-Wei Hsu; Ming O Li
Journal:  Trends Cancer       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.